Fig. 1: Bioinformatic analysis of YTHDF1 expression in HCC tumors and a schematic illustration of engineered stEiNS working for HCC tumor progress and postresection tumor relapse.

a A boxplot of YTHDF1 expression in HCC patients and healthy people isolated from TCGA and Genotype-Tissue Expression determined by Gene Expression Profiling Interactive Analysis. The data were transformed as log2(TPM  +  1). Normal: maxima 4.7099, minima 2.0076, center 3.4694; Tumor: maxima 5.6854, minima 2.3564, center 3.9079. Color key: red, HCC tissues; blue, normal liver tissues. YTHDF1 displays negative associations with (b) disease-free survival in HCC patients. c The prognostic significance of YTHDF1 in HCC patients. Number at risk refers to the number of patients in each experimental group who remain event-free at the specified time points and are still at risk of reaching the study endpoint. d The correlation between YTHDF1 and immune score. e YTHDF1 expression at the mRNA and protein levels in Huh7 and Hepa1-6 cells, with hepatocytes freshly isolated from C57BL/6 mice serving as the control (n = 3 independent experiments). f Schematic illustration of the role of the dynamic locking stEiNS in HCC tumor, which regulates the epigenetic modifications of both tumor cells and M2Φs to enhance the effectiveness of immunotherapy against HCC. Data are expressed as mean ± SD and were determined using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. ****P < 0.0001.